PEGylated Factor VIII Conjugates via Carbohydrate Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Factor VIII (FVIII) therapies for hemophilia A have limited half-life and therapeutic effectiveness due to rapid degradation and immunogenicity, necessitating frequent dosing and reduced circulation time.
Innovation Solution
Conjugation of FVIII with a water-soluble polymer, such as polyethylene glycol (PEG), via carbohydrate moieties to extend its half-life and maintain functional activity, using methods like PEGylation where PEG is attached to the FVIII molecule through oxidized carbohydrate moieties, particularly in the B domain, to enhance stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If FVIII is administered as a standard therapeutic protein, then it can treat hemophilia A, but it has a short half-life and requires frequent dosing
Solution Approach 1:
The patent applies composite materials by conjugating FVIII with polyethylene glycol (PEG) polymers to create a hybrid molecule that combines the therapeutic function of FVIII with the extended circulation properties of PEG. This composite structure increases the hydrodynamic radius and reduces renal clearance, thereby extending the half-life of FVIII from approximately 8-12 hours to 3-4 days, allowing dosing frequency to be reduced from multiple times per week to once or twice per week.
Solution Approach 2:
The patent employs parameter changes by modifying the molecular weight and structure of FVIII through PEGylation. By attaching PEG chains with specific molecular weights (e.g., 5,000 to 20,000 Daltons) to specific sites on FVIII (such as the B domain), the patent alters the pharmacokinetic parameters of FVIII, specifically increasing its half-life and reducing immunogenicity while maintaining its coagulant activity.
2Reliability
If FVIII is purified from plasma, then it can be used for therapy, but it has immunogenicity and reduced circulation time
Solution Approach 1:
The patent uses PEG as an intermediary substance that mediates between the FVIII molecule and the immune system. The PEG layer creates a steric barrier that reduces the recognition of FVIII by anti-FVIII antibodies (inhibitors), thereby reducing immunogenicity and allowing patients with inhibitors to respond to PEGylated FVIII therapy. This intermediary effect extends circulation time and improves therapeutic reliability.
3Duration of action of moving object
If PEG is attached to FVIII to extend half-life, then circulation time increases, but functional activity may be reduced
Solution Approach 1:
The patent applies local quality by selectively targeting specific regions of the FVIII molecule for PEGylation, particularly the B domain, which is less critical for coagulant activity. By concentrating PEG attachment at specific locations rather than uniformly across the entire molecule, the patent minimizes interference with the A1, A2, and C1-C2 domains that are essential for FVIII function, thereby maintaining functional activity while achieving extended circulation time.
Solution Approach 2:
The patent employs partial action by using controlled PEGylation degrees, typically achieving mono- or di-PEGylation per FVIII molecule rather than complete PEGylation of all available sites. This partial modification is sufficient to extend half-life and reduce immunogenicity while avoiding excessive PEG attachment that would sterically hinder the functional domains of FVIII and reduce its coagulant activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEGylated FVIII construct retains full functional activity with an extended half-life, reduced immunogenicity, and increased resistance to thrombin inactivation, allowing for less frequent dosing and improved therapeutic efficacy.
Implementation Method 1
conjugation of FVIII with a water-soluble polymer, such as polyethylene glycol (PEG), via carbohydrate moieties to extend its half-life and maintain functional activity, using methods like PEGylation where PEG is attached to the FVIII molecule through oxidized carbohydrate moieties
Implementation Method 2
PEG is attached to the FVIII molecule through oxidized carbohydrate moieties
Data Source
AI summary
The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.